Veteran pharmaceutical executive brings 30+ years of commercialization, international markets, business development, and M&A experience to support ThyrOxy platform development.

Dr. David Ingbar presents Herald’s evolution into a platform company, advancing multiple indications across two delivery forms, at the Breakthroughs in Critical Care Showcase.

Veteran biopharmaceutical executive brings deep capital-raising, M&A, and product launch experience to lead ThyrOxy platform development.

The USPTO grant extends ThyrOxy intellectual property estate to five issued global patents and protects a novel clinical dosing methodology developed by Herald’s scientific co-founders. The new claims protect direct-to-lung T3 administration with serum-guided dose titration in ARDS.

David Ingbar, MD, and Robert Schumacher, PhD, receive a $1 million Transformational Research Award from the Dr. Ralph and Marian Falk Medical Research Trust.

Herald Therapeutics awarded second place in the Life Science/HealthIT division at the 2025 MN Cup competition, out of 144 competitors.

The Star Tribune features Herald’s work to develop an aerosolized version of ThyrOxy that can be administered more easily and to more patients.

Robert J. Schumacher, PhD, and David H. Ingbar, MD, have received a $106,300 grant from the Minnesota Partnership for Biotechnology and Medical Genomics, through the Translational Product Development Fund.

David Ingbar, MD, and Robert Schumacher, PhD, receive a two-year, $350,000 Catalyst Research Award from the Dr. Ralph and Marion Falk Medical Research Trust.

Herald Therapeutics wins a $10,000 prize in Mayo Clinic’s "‘Walleye Tank’ biomedical innovation competition.

The Star Tribune highlights how patients in Duluth, MN, are among the first to receive ThyrOxy to mitigate lung failure.